South Africa Marks Historic Resumption of Local FMD Vaccine Production

South Africa has achieved a pivotal breakthrough in animal health by releasing its first locally produced Foot-and-Mouth Disease (FMD) vaccine in over two decades. This development, announced on February 6, 2026, by Minister of Agriculture John Steenhuisen, signals a shift toward vaccine self-sufficiency amid ongoing outbreaks affecting eight provinces. The vaccine, developed through extensive research at the Agricultural Research Council (ARC) Onderstepoort Veterinary Research (OVR), addresses a critical gap left by halted production since 2005 due to outdated infrastructure.

Foot-and-Mouth Disease, caused by a picornavirus with seven serotypes including the Southern African Territories (SAT) types prevalent in the region—SAT1, SAT2, and SAT3—devastates livestock industries by causing fever, blisters, and lameness in cattle, sheep, goats, and pigs. In South Africa, the virus has led to significant economic losses since 2019, disrupting exports and farmer livelihoods. The new Onderstepoort FMD Vaccine, registered as G1944 under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act of 1947, promises high potency and year-long immunity tailored to local strains.

The Journey from Production Halt to Revival

Local FMD vaccine manufacturing ceased around 2005 when facilities failed to meet international Good Manufacturing Practice (GMP) standards, forcing reliance on imports, primarily from the Botswana Vaccine Institute (BVI) until late 2025. This dependency exposed vulnerabilities during surges in demand, exacerbated by the 2019 resurgence of outbreaks. Restarting production required overhauling biocontainment level 3 (BSL-3) facilities, adapting virus strains for bioreactor cultivation, and rigorous testing for safety and efficacy.

Government investment spanning two decades culminated in this milestone, with research intensifying from 2010. ARC scientists identified candidate strains circulating in the Southern African Development Community (SADC) region, transitioning from traditional roller bottle methods to modern bioreactors for higher yields. This process not only restored capacity but positioned South Africa to reclaim its FMD-free status from the World Organisation for Animal Health (WOAH), where it currently holds status "free with vaccination" in some zones.

Key Research Institutions Driving the Innovation

At the forefront is the ARC Onderstepoort Veterinary Institute (OVI), a WOAH Reference Laboratory for FMD, renowned for global surveillance and diagnostics. Chief research technician Dr. Faith Peta highlighted the team's commitment: "This first batch represents many years of research... showing South Africa has the capability to develop safe and effective vaccines."

Closely intertwined is the University of Pretoria's (UP) Faculty of Veterinary Science, co-located at the Onderstepoort campus. UP researchers, including Professor Armanda Bastos from the Department of Veterinary Tropical Diseases, lead studies on FMD epidemiology and control strategies. Recent UP-led initiatives, such as a landmark study launched in December 2025 to reform slaughter regulations and minimize industry losses, underscore academic contributions. Collaborative papers from UP and ARC-OVI, like those evaluating vaccine adjuvants and heterologous challenge efficacy, have informed strain selection.

These partnerships exemplify how South African higher education institutions bridge research and application, fostering expertise in transboundary animal diseases. For aspiring researchers, opportunities abound in veterinary science programs at UP and similar faculties.

Step-by-Step Vaccine Development Process

Developing the FMD vaccine involved meticulous phases:

• Strain Isolation and Selection: ARC identified SAT1, SAT2, and SAT3 variants matching regional outbreaks through genomic sequencing and matching at the Pirbright Institute in the UK.
• Adaptation to Bioreactors: Viruses were cultured in vitro, optimizing yields while maintaining antigenicity.
• Potency and Safety Testing: Animal trials confirmed protective immunity lasting up to 12 months, with no reversion to virulence.
• Regulatory Approval: Registration in May 2022 followed compliance with biosafety protocols.
• Pilot Production: Initial 12,900-dose batch using upgraded facilities, now scaling via new infrastructure.

This science-led approach ensures vaccines elicit robust humoral and cellular responses, critical against Africa's diverse FMD topotypes.

First Batch Release: Deployment and Immediate Impacts

The inaugural batch of 12,900 monovalent doses was handed over at ARC-OVR on February 6, 2026, with distribution prioritized to hotspots: Free State (2,300 doses), Eastern Cape (2,600), and others. Production ramps to 20,000 doses weekly from March 2026, reaching 200,000 by 2027, complementing imports from Argentina, Turkey, and Botswana.

Early deployment aims to vaccinate high-risk herds, including those at UP's faculty to safeguard training animals, preventing further spread and economic hemorrhage estimated in billions of rands.

Photo by Juanita Geldenhuys on Unsplash

Economic and Agricultural Ramifications

FMD outbreaks since 2019 have culled thousands of animals, halted exports to FMD-free markets like the EU, and strained smallholder farmers. Local production slashes import costs, enables rapid response, and matches strains precisely—reducing mismatch risks seen in past campaigns. Agbiz economist Wandile Sihlobo emphasized scaling as key to averting crisis.Read the full ministerial announcement

For South Africa's livestock sector, contributing 45% to agricultural GDP, this restores resilience, supporting jobs in farming and veterinary services.

Challenges Overcome and Ongoing Hurdles

Reviving production tackled aging infrastructure, skilled personnel shortages, and stringent BSL-3 requirements. Political debates over procurement and a legal dispute on vaccination control persist, but unified strategies via the Ministerial Task Team prevail.

• Supply bridging via private imports (e.g., 1 million from Biogénesis Bagó).
• Surveillance expansion through ARC's lab network.
• Farmer education on cold-chain handling.

Remaining issues include equitable allocation and biosecurity in communal areas, where UP studies reveal knowledge gaps among small-scale farmers.

Higher Education's Pivotal Role in Veterinary Breakthroughs

South Africa's success underscores the synergy between public research councils and universities. UP's Faculty of Veterinary Science, training future experts at Onderstepoort, conducts field trials and serological monitoring integral to vaccine validation. Recent publications from UP-ARC collaborations, such as efficacy trials against heterologous challenges, bolster global knowledge.

This environment attracts top talent; explore research jobs or higher ed jobs in animal health. For career advice, check how to craft an academic CV.

Future Outlook: Scaling Up and Regional Leadership

New facilities will yield 20 million doses annually, covering the national herd. A 10-year eradication plan targets 90% vaccination coverage, movement controls, and WOAH re-zoning. Regionally, SADC benefits from shared strains and expertise, potentially curbing cross-border spread.

Investments in biotech training at institutions like UP position South Africa as an African hub for veterinary innovation. Professionals can advance via South African academic opportunities or university jobs.

Stakeholder Perspectives and Next Steps

Farmers welcome the news but urge acceleration, per Milk SA's Dr. Mark Chimes. Minister Steenhuisen vows a "science-led offense," backed by President Ramaphosa. For researchers, this validates long-term funding; check postdoc career tips.

ARC's detailed vaccine development statement (PDF) outlines the roadmap.

Photo by Ryan Byrne on Unsplash

Conclusion: A New Era for South African Animal Health Research

The resumption of FMD vaccine production epitomizes resilience in South African science, blending ARC ingenuity with university prowess. As production scales, expect restored exports, protected livelihoods, and enhanced research ecosystems. Aspiring academics, rate your professors at Rate My Professor, browse higher ed jobs, or seek career advice. This milestone inspires the next generation in veterinary and biotech fields.